
Brainsway To Report Third Quarter 2024 Financial Results On November 12, 2024
Date: | Tuesday, November 12, 2024 |
Time: | 8:30 AM Eastern Time |
United States: | 1-877-300-8521 |
International: | 1-412-317-6026 |
Israel: | 1-80-921-2373 |
Conference ID: | 10193781 |
Webcast: |
The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, . Please access the Company's website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMSTM) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
...
Investors:
Brian Ritchie
LifeSci Advisors
...


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment